Biomerica Receives Egyptian Approval for Full Portfolio of Diagnostic Tests

Biomerica has received Egyptian Drug Authority approval for its full portfolio of rapid diagnostic tests, including at-home tests for colon disease, breast cancer, prostate cancer, kidney disease, and ulcers. The approval covers six tests and could expand the company's market reach. Biomerica's shares rose over 4% in pre-market trading after closing at $2.50, up 1.62% on Wednesday.